key: cord-0841547-8r08d1mm
authors: Scoccimarro, Daniele; Panichi, Lorenzo; Ragghianti, Benedetta; Silverii, Antonio; Mannucci, Edoardo; Monami, Matteo
title: Sars-CoV2 vaccine hesitancy in italy: A survey on subjects with diabetes
date: 2021-09-10
journal: Nutr Metab Cardiovasc Dis
DOI: 10.1016/j.numecd.2021.09.002
sha: bf6c09ec98be2c396992be3186b7d999aefb326e
doc_id: 841547
cord_uid: 8r08d1mm

Background and Aims Vaccine Hesitancy (VH) is a relevant obstacle for the COVID-19 vaccination campaign. The aim of this study is to assess the proportion of subjects unwilling to vaccinate among patients with type 1 (T1DM) and 2 (T2DM) diabetes, exploring factors associated with vaccine hesitancy. Methods and results A purposely created interview was delivered from physicians to a consecutive series of adult (>18 years) subjects with diabetes referring to the Diabetes Outpatient Clinic of Careggi Hospital, Florence, from January 1st to April 30th 2021. Out of 502 subjects enrolled, 92 were vaccine hesitant respondents (18.3%); the corresponding figure for T1DM and T2DM was 13.0% (N = 14), and 19.9% (N = 78), respectively. After adjusting for age, higher HbA1c (1.07 [1.02 - 1.13], p=0.008) and triglycerides levels (1.03 [1.01 - 1.06], p=0.011) were positively associated with vaccine hesitancy, among patients with T1DM. At multivariate analysis, after adjusting for age, creatinine, and statin use, patients with T2DM affected by obesity (9.98 [4.89 - 9.59], p < 0.01) and with lower levels of creatinine (0.36 [0.21 - 0.54], p = 0.029) were more likely to refuse COVID vaccination. Conclusions Hesitancy toward COVID-19 vaccination among subjects with diabetes is not negligible and seems to be more prevalent in individuals with lower adherence to medical prescriptions and/or reduced concerns over their health. This suggests the need for specific interventions to increase awareness and counter prejudices on vaccines.

The Italian COVID-19 vaccination campaign, started on December 2020 and aimed at covering the entire population aged>16 years 1 , uses two m-RNA (Comirnaty®, Pfizer/BioNTech, and mRNA-1273, Moderna) and two DNA (Vaxzevria®, AstraZeneca, and Ad26.COV2.S, J&J) vaccines [2] [3] [4] [5] . The first available doses were used to immunize health professionals and nursing home residents. The second phase of the campaign targeted high-risk categories 6 , including part of patients with diabetes 7 . Priority in vaccination was established for subjects with type 1 diabetes, and those with type 2 diabetes treated with at least two drugs 8 . In fact, diabetes is associated with an increased risk of infection from SARS-CoV-2 9 and poorer outcomes 9, 10 . Vaccine Hesitancy 11 (VH) is a relevant obstacle for the vaccination campaign. Available surveys worldwide report a prevalence of VH for COVID-19 ranging from 14 to 38% [12] [13] [14] [15] . To our knowledge, only one study on VH in patients with type 2 diabetes in Italy has been published so far, reporting the results of online-delivered (Facebook) self-administered questionnaire 16 The aim of this study, performed on a clinical-based sample, is to assess the proportion of subjects unwilling to vaccinate among patients with type 1 and 2 diabetes, exploring factors associated with vaccine hesitancy.

Data were collected using a purposely created interview, delivered from physicians to a consecutive series of adult (>18 years) subjects with diabetes referring to the Diabetes Outpatient Clinic of Careggi Hospital, Florence, from January 1 st to April 30 th, 2021, who provided their informed consent. Patients not fluent in Italian and incapable of answering because of concurrent conditions (e.g., dementia) were excluded. The survey collected demographic and anamnestic parameters and the intention to COVID-19 vaccination (see Supplementary Materials). Further clinical parameters were retrieved from clinical records. Subjects were considered as vaccination hesitant, if they were unsure, somewhat, or extremely unlikely to get vaccinated, those with certified contraindications were excluded from the analysis. Analyses were performed separately in Type 1 (T1DM) and Type 2 (T2DM) diabetes. Two-tailed Ttests and chi-square tests were used for assessing between-group differences for continuous and categorial variables, respectively. All variables significantly (p<0.05) associated with VH were adjusted for age. Furthermore, a multivariate logistic regression analysis was performed, with VH as an outcome, and age, and patients' characteristics significantly associated with VH at univariate analysis as covariates. All analyses were performed using IBM SPSS Statistics 27.0. The study protocol was approved by the local Ethical Board of Florence (Ref. 19932_OSS) J o u r n a l P r e -p r o o f

Of 538 patients invited, 36 of them (12 and 26 with type 1 and 2 diabetes, respectively) refused to participate. The clinical characteristics of refusers did not differ significantly from those of enrolled subjects (data not shown). The sample consisted of 502 subjects, of whom 108 were affected by T1DM and 394 by T2DM. The proportion of vaccine-hesitant respondents was 18.3% (N=92); the corresponding figure for T1DM and T2DM was 13.0% (N = 14), and 19.9% (N = 78), respectively (p=0.48 between groups). The principal characteristics of the two samples were summarized in Table 1 . Among subjects with T1DM, vaccination hesitant respondents had significantly lower BMI, and creatinine, and higher HbA1c, total cholesterol, and triglycerides levels; in addition, among hesitant subjects, a lower proportion of individuals receiving statins and anti-hypertensive drugs was observed ( 

The proportion of hesitant subjects among people with diabetes is not negligible, even though diabetes is a well-known risk factor for severe COVID-19 9,10,17 . The results obtained are similar to those of a previous survey 16 , collecting data from volunteers using a web-based self-reported questionnaire. In the present study, data were collected using an interview, thus reducing the chance of misunderstandings; on the other hand, the administration of the interview was performed by physicians recommending vaccination, possibly affecting patients' answers. In addition, the present study was performed on a consecutive series of patients, avoiding the biases related to selfselection typical of voluntary web-based surveys; however, the sample was composed only of patients referred to a single Clinic, unrepresentative of the general population with diabetes. Despite those differences, the present study and the previous survey 16 provided similar results, confirming the validity of the estimate of the prevalence of vaccine hesitancy. The exploration of determinants of vaccine hesitancy is useful for designing specific interventions. VH was associated with poor glucose and lipid control in T1DM, and with obesity in T2DM, suggesting that hesitancy could be more prevalent in individuals with lower adherence to medical prescriptions and/or reduced concerns over their health 18 . Obesity and poor glycaemic control are major determinants of worse prognosis among patients with COVID-19 19 ; as a consequence, those with the highest risk of severe COVID-19 could be the least prone to vaccination. Further features associated with VH may have remained undetected in the present study, due to the limited sample size. Interestingly, hesitancy toward the COVID19 vaccine was not significantly associated with hesitancy toward other vaccinations. In conclusion, hesitancy toward COVID-19 vaccination among subjects with diabetes in Italy is not negligible, suggesting the need for specific interventions to increase awareness and counter prejudices on vaccines. 

Piano vaccinale del commissario straordinario

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Epub ahead of print

Vaccinazione anti-SARS-CoV-2/COVID-19 -Piano strategico. Elementi di preparazione e di implementazione della strategia vaccinale

Risk factors for severe and critically ill COVID-19 patients: A review

SARS-CoV-2 and COVID-19 in diabetes mellitus. Population-based study on ascertained infections, hospital admissions and mortality in an Italian region with ∼5 million inhabitants and ∼250,000 diabetic people

Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily

Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants

Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19

A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. The Lancet Infectious Diseases

Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine

Sydney Health Literacy Lab COVID-19 group. Willingness to vaccinate against COVID-19 in Australia

Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey. Vaccines (Basel)

Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis

Medication Adherence With Diabetes Medication: A Systematic Review of the Literature

Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19)

Vaccine Hesitancy (VH) is a relevant obstacle for the vaccination campaign

The proportion of hesitant subjects with diabetes is not negligible, despite the fact that diabetes is a well-known risk factor for severe COVID-19